LOOKING FOR MORE INFORMATION DURING COVID-19?
See how we can provide support for your patients during this uncertain time.
TAKE CHARGE OF UC+CD FOR YOUR BIO-NAÏVE PATIENTS
STELARA® FOR LASTING* REMISSION
For the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease.
*In both the UC and CD studies, many patients achieved clinical remission at 1 Year with STELARA®.
RAPID RESPONSE
Many patients achieved clinical response as early as Week 8 in UC and Week 6 in CD in clinical trials1†
LASTING REMISSION
Many patients achieved clinical remission at 1 year in the UC and CD clinical trials1,2‡
HISTO-ENDOSCOPIC MUCOSAL IMPROVEMENT (HEMI) IN UC
The first and only FDA-approved UC treatment to achieve HEMI. Some patients with UC achieved HEMI with STELARA® at the designated time points (Week 8 and 1 Year) in clinical trials1,2§
DEMONSTRATED SAFETY PROFILE
The safety profile in UC and CD studies was consistent with that seen in other approved indications1
STELARA®—APPROVED FOR ULCERATIVE COLITIS (UC)
The first and only FDA-approved UC treatment to achieve HEMI1
STELARA®—3 YEARS OF EFFICACY AND SAFETY DATA IN CROHN’S DISEASE (CD)
In the Phase 3 clinical trials and open-label LTE1-3
Janssen CarePath is your one source for access, affordability, and treatment support for your patients
Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial options for eligible patients, and provides ongoing support to help patients start and stay on STELARA® as prescribed.
Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 ᴀᴍ to 8:00 ᴘᴍ ET
Sign Up or Log In to the Provider Portal at JanssenCarePathPortal.com where you can request and review benefits investigations, enroll eligible patients in the Janssen CarePath Savings Program, and view Savings Program transactions as requested by the patient.
Visit JanssenCarePath.com
REGISTER FOR UPDATES
Register to receive the latest information and materials about STELARA® as they become available. You’ll also receive important information that will support your treatment of patients. Please complete the registration form below.
The information you provide will only be used by Janssen Biotech, Inc., our affiliates, and our service providers, to send you STELARA®-related information and to fulfill any optional requests you may indicate. You may unsubscribe here or by following the instructions in the messages you receive. Our Privacy Policy governs the use of the information you provide. By providing the information and selecting the Submit button, you indicate you read, understand, and agree to these terms.
*Required fields.
Bio-naïve=naïve to biologic treatment; CD=Crohn’s disease; CDAI=Crohn's Disease Activity Index; LTE=long-term extension; UC=ulcerative colitis.
†In UC, clinical response was defined as a decrease from baseline in the Mayo score by ≥30% and ≥2 points, with either a decrease from baseline in the rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1. In CD, clinical response was defined as reduction in CDAI score of ≥100 points or CDAI score of <150.
‡In UC, clinical remission was defined as Mayo stool frequency subscore of 0 or 1, Mayo rectal bleeding subscore of 0, and Mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability). In CD, clinical remission was defined as a CDAI score of <150.
§HEMI was defined as combined endoscopic improvement (Mayo endoscopy subscore of 0 or 1) and histologic improvement of the colon tissue (neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue).
References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc. 3. Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48(1):65-77.
